The demand for compounding pharmacies in the U.S. is projected to grow from USD 5.6 billion in 2025 to USD 12.8 billion by 2036, with a compound annual growth rate (CAGR) of 7.8%. The market will be primarily driven by 503A pharmacies, which are expected to hold a 65% market share, and oral medications, making up 33% of demand. Key growth drivers include regulatory approvals, reimbursement expansions, and rising clinical infrastructure investments, particularly in the South, which is anticipated to grow at 8.1%. Analysts indicate a shift towards more value-driven, specification-focused procurement in this sector, as demand evolves from volume-based growth to tailored solutions that meet specific healthcare needs.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.futuremarketinsights.com/reports/us-compounding-pharmacies-market
